TS-1® Capsule received TW NHI approval for Treatment of Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer

TS-1® Capsule received TW NHI approval for Treatment of Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer

2020.1.31 最新消息

...

More

LONSURF® get NHI reimbursement for metastatic colorectal cancer treatment since Dec/01/2018.

LONSURF® get NHI reimbursement for metastatic colorectal cancer treatment since Dec/01/2018.

2018.11.16 最新消息

...

More

TS-1® Capsule approved in Taiwan for the Treatment of Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer.

TS-1® Capsule approved in Taiwan for the Treatment of Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer.

2018.9.12 最新消息

...

More

TTY Biopharm and Taiho Pharmaceutical entered in an exclusive agreement of LONSURF® has received license approval from TFDA.

TTY Biopharm and Taiho Pharmaceutical entered in an exclusive agreement of LONSURF® has received license approval from TFDA.

2018.1.15 最新消息

...

More

Mr. Rongjin Lin has been sentenced with an execution of ten years in prison, and the confiscation of illegal earnings.

Mr. Rongjin Lin has been sentenced with an execution of ten years in prison, and the confiscation of illegal earnings.

2017.9.1 最新消息

...

More

MolMed and TTY Biopharm entered into an exclusive agreement to commercialise Zalmoxis® in certain Asian territories

MolMed and TTY Biopharm entered into an exclusive agreement to commercialise Zalmoxis® in certain Asian territories

2017.6.30 最新消息

...

More

MolMed and TTY Biopharm entered into a term sheet to commercialise Zalmoxis® in certain Asian territories

MolMed and TTY Biopharm entered into a term sheet to commercialise Zalmoxis® in certain Asian territories

2017.2.8 最新消息

...

More

Overcame Barriers- Anticancer Agent S-1 Capsule (S-1) Received Reimbursement for Treatment of Gastric Cancer

Overcame Barriers- Anticancer Agent S-1 Capsule (S-1) Received Reimbursement for Treatment of Gastric Cancer

2016.12.13 最新消息

...

More

TTY Biopharm’s Anticancer Agent S-1 Received Reimbursement for Adjuvant Treatment of Locally-advanced Gastric Cancer

TTY Biopharm’s Anticancer Agent S-1 Received Reimbursement for Adjuvant Treatment of Locally-advanced Gastric Cancer

2016.12.13 最新消息

...

More

TTY Biopharm received an exclusive license from Taiho Pharmaceutical to sell an anticancer drug in Taiwan market

TTY Biopharm received an exclusive license from Taiho Pharmaceutical to sell an anticancer drug in Taiwan market

2016.10.18 最新消息

...

More

TOP